Abstract:Drug design is usually understood as “an inventive process of finding new medications based on the knowledge of the biological target” – according to the Wikipedia definition – where “drug” is usually defined as a relatively small organic ligand binding to a biomolecule to either inhibit or promote its activity. [1] Methods of thus-defined drug design are well established in the early stages of drug discovery and focus mainly on identifying new chemical entities (NCEs) – molecules with desired biological activity. Along with activity, however, drugs must possess acceptable ADMET (Absorption, Distribution, Metabolism, Elimination, and Toxicity) properties. Although a few recent trends push ADMET optimization into drug design, these properties are still largely neglected until the lead optimization phase occurring later in drug discovery when the available chemical space is already narrowed by affinity and selectivity concerns. Usually one group of drug discovery researchers hands out lead molecules to a separate group of drug development scientists: “Our job is done, here are the active molecules. Now you worry about their other properties.” This separation could, and often does, lead to frustrating failures where all the lead compounds may, for example, turn out to be insoluble in water, impermeable via the intended route of administration, unacceptably metabolized by enzymes common to co-medications, or produce unacceptable adverse effects. All the effort and cost of discovering them would then be wasted. Authors of this article strongly believe in “ADMET design” – a paradigm where ADMET properties are included in the earliest stages of drug discovery and treated on equal footing with biological efficacy. This multidimensional search and optimization should be a normal function of the team of discovery chemists and other pharmaceutical scientists. The difficulty is that humans are not well-adapted to thinking in more than a few dimensions at once. In silico approaches are the solution as they facilitate integration of multiple variables and the most efficient use of experimental data. In the following sections we focus on machine learning approaches, such as Artificial Neural Networks (ANN) [2] or Support Vector Machines (SVM) [3], to QSAR/QSPR modeling [4] of ADMET properties. In QSAR/QSPR, chemical structures are encoded by calculated values of molecular descriptors serving as inputs to mathematical predictive models. ANN models, in particular, have been determined to be superior predictors over other methods. [5] Training several ANN or SVM and taking an arithmetic average of their outputs as the final answer usually enhances accuracy of prediction and is known as ANN Ensemble (ANNE) or SVM Ensemble (SVME) approaches. [6] Some researchers regard these techniques as “black boxes” meaning that although ANNE or SVME models can produce numerical outputs, their internal complexity precludes any descriptive interpretation of these results. Contrary to these stereotypical beliefs, predictive mathematical models of this type are quite interpretable and thus amenable to a direct use in drug design. We demonstrate this claim on specific examples.

Benchmarking ML in ADMET predictions: the practical impact of feature representations in ligand-based models

MTGL-ADMET: A Novel Multi-task Graph Learning Framework for ADMET Prediction Enhanced by Status-Theory and Maximum Flow.

ADMET Property Prediction Via Multi-Task Graph Learning under Adaptive Auxiliary Task Selection

Accurate ADMET Prediction with XGBoost

Interpretable-ADMET: a web service for ADMET prediction and optimization based on deep neural representation

ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries

Systematic Evaluation of Local and Global Machine Learning Models for the Prediction of ADME Properties

Step Change Improvement in ADMET Prediction with PotentialNet Deep Featurization

Transformer-based deep learning method for optimizing ADMET properties of lead compounds

PharmaBench: Enhancing ADMET benchmarks with large language models

Busting the Black Box Myth: Designing out Unwanted ADMET Properties with Machine Learning Approaches

Prospective Validation of Machine Learning Algorithms for Absorption, Distribution, Metabolism, and Excretion Prediction: An Industrial Perspective

Binding Affinity Prediction with 3D Machine Learning: Training Data and Challenging External Testing

In Silico Admet Prediction : Recent Advances, Current Challenges and Future Trends

ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties

Multi-task ADME/PK Prediction at Industrial Scale: Leveraging Large and Diverse Experimental Datasets

FP-ADMET: a compendium of fingerprint-based ADMET prediction models

On Machine Learning Approaches for Protein-Ligand Binding Affinity Prediction

ADMET Evaluation in Drug Discovery: 15. Accurate Prediction of Rat Oral Acute Toxicity Using Relevance Vector Machine and Consensus Modeling

Machine Learning Small Molecule Properties in Drug Discovery